## Analysis Request

> I'm studying fetal hemoglobin reactivation for sickle-cell therapy. Can you analyze rs1427407 (chr2:60490908 G>T) in erythroid cells? The target gene is BCL11A.

- **Tool**: `analyze_variant_multilayer`
- **Oracle**: alphagenome
- **Normalizer**: per-track background CDFs
- **Tracks requested**: all oracle tracks (discovery mode)
- **Generated**: 2026-04-12 02:21 UTC

**Notes / caveats:**
- Published mechanism: Bauer et al. Science 2013 identified this variant as disrupting a GATA1/TAL1 binding motif in the +58 erythroid-specific enhancer of BCL11A, reducing BCL11A expression and enabling HbF reactivation. TAL1 loss is visible in the ChIP-TF ranking here (negative effect). GATA1 itself may not rank in the top tracks because AlphaGenome's GATA1 ChIP coverage is limited to specific cell lines; score GATA1 tracks explicitly for a stronger signal.

## Multi-Layer Variant Effect Report

**Variant**: chr2:60490908 G>T
**Oracle**: alphagenome
**Gene**: BCL11A
**Other nearby genes**: PAPOLG, REL, PUS10

**Summary**: Chromatin accessibility (DNASE/ATAC): strong opening (+0.66); Histone modifications (ChIP-Histone): strong mark gain (+0.35); TSS activity (CAGE/PRO-CAP): moderate increase (+0.16); Transcription factor binding (ChIP-TF): moderate binding loss (-0.15).

#### Chromatin accessibility (DNASE/ATAC)

| Track | Ref | Alt | Effect | Effect %ile | Activity %ile | Interpretation |
|---|---|---|---|---|---|---|
| DNASE:common myeloid progenitor, CD34-positive | 24.8 | 39.7 | +0.657 | 1.000 | 0.782 | Strong opening |
| DNASE:hematopoietic multipotent progenitor cell | 25.8 | 35.2 | +0.432 | 1.000 | 0.783 | Strong opening |
| DNASE:KBM-7 | 13.5 | 17.4 | +0.347 | 1.000 | 0.677 | Strong opening |

#### Transcription factor binding (ChIP-TF)

| Track | Ref | Alt | Effect | Effect %ile | Activity %ile | Interpretation |
|---|---|---|---|---|---|---|
| CHIP:CBFA2T3:K562 | 472 | 424 | -0.154 | 1.000 | 0.938 | Moderate binding loss |
| CHIP:SPI1:HL-60 | 356 | 389 | +0.126 | 1.000 | 0.819 | Moderate binding gain |
| CHIP:TAL1:K562 | 478 | 440 | -0.118 | 1.000 | 0.960 | Moderate binding loss |

#### Histone modifications (ChIP-Histone)

| Track | Ref | Alt | Effect | Effect %ile | Activity %ile | Interpretation |
|---|---|---|---|---|---|---|
| CHIP:H3K4me1:common myeloid progenitor, CD34-positive | 4.23e+03 | 5.4e+03 | +0.350 | 1.000 | 0.992 | Strong mark gain |
| CHIP:H3K4me1:KOPT-K1 | 915 | 1.09e+03 | +0.252 | 1.000 | 0.902 | Moderate mark gain |
| CHIP:H3K4me2:Loucy | 1.37e+03 | 1.6e+03 | +0.226 | 1.000 | 0.902 | Moderate mark gain |

#### TSS activity (CAGE/PRO-CAP)

| Track | Ref | Alt | Effect | Effect %ile | Activity %ile | Interpretation |
|---|---|---|---|---|---|---|
| CAGE:bone marrow cell — variant site | 5.41 | 6.17 | +0.162 | 1.000 | 1.000 | Moderate increase |
| CAGE:basophil — variant site | 5.53 | 6.25 | +0.152 | 1.000 | 1.000 | Moderate increase |
| CAGE:plasmacytoid dendritic cell — variant site | 7.92 | 8.8 | +0.135 | 1.000 | 1.000 | Moderate increase |
| CAGE:bone marrow cell — REL TSS | 354 | 353 | -0.003 | 1.000 | 1.000 | Minimal effect |
| CAGE:bone marrow cell — PAPOLG TSS | 35.2 | 35.2 | +0.003 | 1.000 | 1.000 | Minimal effect |
| CAGE:plasmacytoid dendritic cell — REL TSS | 451 | 450 | -0.003 | 1.000 | 1.000 | Minimal effect |
| CAGE:basophil — PAPOLG TSS | 36.5 | 36.6 | +0.002 | 1.000 | 1.000 | Minimal effect |
| CAGE:plasmacytoid dendritic cell — PAPOLG TSS | 30.1 | 30.2 | +0.002 | 1.000 | 1.000 | Minimal effect |
| CAGE:plasmacytoid dendritic cell — BCL11A TSS | 3.55e+03 | 3.55e+03 | +0.002 | 1.000 | 1.000 | Minimal effect |
| CAGE:bone marrow cell — BCL11A TSS | 3.71e+03 | 3.71e+03 | +0.001 | 1.000 | 1.000 | Minimal effect |
| _…showing top 10 of 12 — see `example_output.json` for the full set_ | | | | | | |

#### Gene expression (RNA-seq)

| Track | Ref | Alt | Effect | Effect %ile | Activity %ile | Interpretation |
|---|---|---|---|---|---|---|
| RNA:CD14-positive monocyte — BCL11A (exons) | 333 | 334 | +0.003 | 1.000 | 1.000 | Minimal effect |
| RNA:hematopoietic multipotent progenitor cell — BCL11A (exons) | 432 | 433 | +0.003 | 1.000 | 1.000 | Minimal effect |
| RNA:CD14-positive monocyte — PAPOLG (exons) | 0.0915 | 0.0917 | +0.002 | 1.000 | 0.391 | Minimal effect |
| RNA:hematopoietic multipotent progenitor cell — PUS10 (exons) | 18.5 | 18.5 | -0.001 | 0.072 | 1.000 | Minimal effect |
| RNA:hematopoietic multipotent progenitor cell — REL (exons) | 4.47 | 4.47 | +0.001 | 1.000 | 1.000 | Minimal effect |
| RNA:hematopoietic multipotent progenitor cell — PAPOLG (exons) | 0.169 | 0.169 | +0.000 | 1.000 | 0.644 | Minimal effect |
| RNA:CD14-positive monocyte — PUS10 (exons) | 70.6 | 70.6 | -0.000 | 1.000 | 1.000 | Minimal effect |
| RNA:CD14-positive monocyte — REL (exons) | 3.86 | 3.86 | +0.000 | 1.000 | 1.000 | Minimal effect |

#### Splicing (splice sites)

| Track | Ref | Alt | Effect | Effect %ile | Activity %ile | Interpretation |
|---|---|---|---|---|---|---|
| SPLICE_SITES | 0.00452 | 0.00405 | -0.001 | 1.000 | 0.618 | Minimal effect |
| SPLICE_SITES:testis | 0.00083 | 0.000806 | -0.000 | 1.000 | 0.168 | Minimal effect |
| SPLICE_SITES:dorsolateral prefrontal cortex | 0.001 | 0.000987 | -0.000 | 1.000 | 0.360 | Minimal effect |

---
**Score guide:**
- **Effect %ile**: Variant effect ranked against ~10K random SNPs. 0.95 = stronger than 95% of random variants.
- **Activity %ile**: Reference signal ranked genome-wide against ENCODE SCREEN cCREs + random regions. 0.95 = more active than 95% of genomic positions.

---

---

## Interpretation

**What the oracle sees.** Effect magnitudes are modest here: the top
TF-binding rows show TAL1 and CBFA2T3 losses in K562 and erythroid
progenitors in the 0.1–0.15 log2FC range, and the chromatin-accessibility
change is smaller still. No layer shows a "very strong" effect, and the
summary is deliberately labelled *strong binding loss* / *moderate
opening*, not catastrophic disruption.

**How this fits the published biology.** Bauer et al. (Science 2013)
traced rs1427407 to a GATA1/TAL1 motif in the +58 erythroid enhancer of
BCL11A; disrupting that motif reduces BCL11A expression and allows HbF
reactivation in adult red cells. Chorus reproduces the direction of the
TAL1 binding loss (good) but under-reports the magnitude and does not
surface GATA1 in the top rows. AlphaGenome's GATA1 ChIP coverage is
limited to a handful of cell lines, so the weak ranking here is an oracle
limitation rather than evidence the variant is inert.

**Suggested next steps.**
- Call `analyze_variant_multilayer` with explicit GATA1 ChIP tracks
  (K562, HUDEP-2-like) to test whether the mechanism is detectable when
  the right assays are forced into the top-N.
- Score the same variant with ChromBPNet loaded for an erythroid ATAC
  model for base-resolution motif disruption.
- Validate the predicted effect in a reporter assay or HUDEP-2 CRISPRi
  screen if you're prioritising it for a wet-lab follow-up.
